These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11673334)

  • 21. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
    Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
    Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent.
    Ahmed WH
    Expert Rev Med Devices; 2007 Mar; 4(2):117-20. PubMed ID: 17359218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff.
    Pires NM; van der Hoeven BL; de Vries MR; Havekes LM; van Vlijmen BJ; Hennink WE; Quax PH; Jukema JW
    Biomaterials; 2005 Sep; 26(26):5386-94. PubMed ID: 15814137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus-eluting stents: safe and effective in the treatment of in-stent restenosis.
    Neumann FJ
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):163-4. PubMed ID: 16158398
    [No Abstract]   [Full Text] [Related]  

  • 27. Images in Cardiovascular Medicine. True three-dimensional reconstructed images showing lumen enlargement after sirolimus-eluting stent implantation.
    Tanabe K; Gijsen FJ; Degertekin M; Ligthart JM; Oortman RM; Serruys PW; Slager CJ
    Circulation; 2002 Nov; 106(22):e179-80. PubMed ID: 12451017
    [No Abstract]   [Full Text] [Related]  

  • 28. Coronary artery bypass is superior to drug-eluting stents in multivessel coronary artery disease.
    Guyton RA
    Ann Thorac Surg; 2006 Jun; 81(6):1949-57. PubMed ID: 16731112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CARI guidelines. Vascular access surveillance.
    Polkinghorne K;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S1-11. PubMed ID: 18713118
    [No Abstract]   [Full Text] [Related]  

  • 30. Angioscopic findings after drug-eluting stent implantation.
    Takano M; Mizuno K
    Herz; 2007 Jun; 32(4):281-6. PubMed ID: 17607534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory issues facing the development of drug-eluting stents: a US FDA perspective.
    Boam AB
    Expert Rev Med Devices; 2006 May; 3(3):297-300. PubMed ID: 16681451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arterial stents as a therapeutic platform.
    Roitberg B
    Surg Neurol; 2003 Mar; 59(3):146-7. PubMed ID: 12693402
    [No Abstract]   [Full Text] [Related]  

  • 33. A meta-analysis of the effect of thiazolidinediones on in-stent restenosis after coronary stent implantation.
    Chen L; Tonkin A
    Am Heart J; 2007 Nov; 154(5):e41; author reply e43. PubMed ID: 17967579
    [No Abstract]   [Full Text] [Related]  

  • 34. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
    Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug-eluting stents: breakthrough or time bomb].
    Lüscher TF; Silber S
    Herz; 2007 Jun; 32(4):265-7. PubMed ID: 17607531
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-eluting stents.
    Chieffo A; Colombo A
    Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neointimal formation following drug-eluting stents: physiology, timeline, and the influence of drug delivery systems.
    Young JJ
    Rev Cardiovasc Med; 2007; 8 Suppl 1():S3-10. PubMed ID: 17401309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of an external Dacron sheath for the prevention of vein graft disease: the Extent study.
    Murphy GJ; Newby AC; Jeremy JY; Baumbach A; Angelini GD
    J Thorac Cardiovasc Surg; 2007 Aug; 134(2):504-5. PubMed ID: 17662798
    [No Abstract]   [Full Text] [Related]  

  • 39. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.
    Lemos PA; Saia F; Ligthart JM; Arampatzis CA; Sianos G; Tanabe K; Hoye A; Degertekin M; Daemen J; McFadden E; Hofma S; Smits PC; de Feyter P; van der Giessen WJ; van Domburg RT; Serruys PW
    Circulation; 2003 Jul; 108(3):257-60. PubMed ID: 12860901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
    J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.